Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
CureGene has dosed the first participant in a randomized Phase 1 study of CG-0416, an oral liver-targeted THR-β prodrug whose weight-loss and muscle-preservation claims remain based on preclinical evidence.
Discover why Ascletis’ monthly ASC36 and ASC36_35 obesity drugs matter, and which clinical risks could determine their future.
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.
Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.